Related Experiment Video
Updated: Sep 13, 2025

Fluorescent Leakage Assay to Investigate Membrane Destabilization by Cell-Penetrating Peptide
Published on: December 19, 2020
A Short Peptide Inhibitor of Measles Virus Fusion Protein that Exhibits Passive Membrane Permeability
Ziwei Gao1, Jiei Sasaki2, Tateki Suzuki2
1Department of Chemistry & Biotechnology, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.
Abstract:
In this study, a passively membrane-permeable short peptide inhibitor targeting the measles virus fusion protein (MeV-F) is reported. Measles virus (MeV) is highly contagious, yet no approved antiviral drugs are currently available. MeV-F plays a crucial role in viral infection, making it an attractive target for drug development. The fusion inhibitor peptide (FIP) is a well-known short peptide that binds to MeV-F and prevents its structural rearrangement. However, improving both inhibitory activity and passive membrane permeability is essential for developing orally available MeV-F inhibitors. Herein, FIP derivatives are explored through hydrogen-to-fluorine substitution and a derivative with enhanced inhibitory activity (IC50 = 90 nM) and passive membrane permeability (Pe = 1.4 × 10-6 cm s-1) was identified. This study highlights the potential of the long-studied fusion inhibitor peptide as a promising lead compound for the development of orally available drugs against measles infection.
Insights
Researchers developed a new measles virus fusion protein (MeV-F) inhibitor. This peptide shows improved activity and membrane permeability, offering potential for orally available measles antiviral drugs.
Area of Science:
- Virology
- Medicinal Chemistry
- Drug Discovery
Background:
- Measles virus (MeV) is highly contagious with no approved antiviral treatments.
- The measles virus fusion protein (MeV-F) is essential for viral entry and a key drug target.
- Existing fusion inhibitor peptides (FIPs) require enhanced activity and membrane permeability for oral drug development.
Purpose of the Study:
- To design and synthesize novel MeV-F inhibitors with improved oral bioavailability.
- To enhance both the inhibitory potency and passive membrane permeability of FIPs.
Main Methods:
- Chemical modification of FIPs using hydrogen-to-fluorine substitution.
- Evaluation of inhibitory activity (IC50) and passive membrane permeability (Pe) of FIP derivatives.
Main Results:
- Identified a novel FIP derivative with significantly enhanced inhibitory activity (IC50 = 90 nM).
- Achieved improved passive membrane permeability (Pe = 1.4 × 10^-6 cm/s) in the FIP derivative.
- Demonstrated the potential of modified FIPs as orally available MeV-F inhibitors.
Conclusions:
- The developed FIP derivative represents a promising lead compound for oral measles antiviral therapy.
- Hydrogen-to-fluorine substitution is an effective strategy for optimizing FIP properties.
- Further development of these FIP derivatives could lead to the first orally available measles treatment.
More Related Videos
08:09Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
07:53A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
Published on: January 9, 2019
Related Concept Videos
Protein Diffusion in the Membrane
Single-pass Transmembrane Proteins
Membrane Fluidity